STUDY OBJECTIVE Increased acute kidney injury (AKI) incidence has been reported in patients receiving piperacillin-tazobactam (PTZ) therapy compared with other b-lactams. The authors sought to determine if the addition of b-lactamase inhibitors impacts AKI incidence by comparing patients treated with PTZ or ampicillin-sulbactam (SAM The use of piperacillin-tazobactam (PTZ) in combination with vancomycin (VAN) has been associated with elevated rates of acute kidney injury (AKI) in many small retrospective studies. Incidence rates of AKI range from 9.5% to 34.8%, depending on the target population, with critically ill populations having higher incidence of AKI.
The use of piperacillin-tazobactam (PTZ) in combination with vancomycin (VAN) has been associated with elevated rates of acute kidney injury (AKI) in many small retrospective studies. Incidence rates of AKI range from 9.5% to 34.8%, depending on the target population, with critically ill populations having higher incidence of AKI. [1] [2] [3] [4] [5] [6] [7] [8] The most common comparator agent in these studies was cefepime, [4] [5] [6] because PTZ and cefepime share a similar niche in antipseudomonal therapy. In these comparisons, PTZ was associated with higher rates of AKI versus cefepime. The mechanism for the increased incidence of AKI is unknown. However, PTZ is unique, compared with cefepime, in that it contains a b-
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lactam as well as a b-lactamase inhibitor that is structurally similar to other b-lactams.
Ampicillin-sulbactam (SAM) is another intravenous b-lactam/b-lactamase inhibitor combination that is commonly used in practice. No studies examining the difference in AKI incidence between these two agents are available. The primary objective of this study was to determine if there is a significant difference in the rate of AKI in patients treated with PTZ or SAM. We hypothesize that these groups have similar rates of AKI and therefore the observed increase in AKI with PTZ is not related to coadministration of a b-lactam with a b-lactamase inhibitor.
Methods
This was an institutional review board-approved retrospective cohort study conducted at University of Kentucky HealthCare between September 1, 2007, and September 30, 2015. Adult patients receiving PTZ or SAM for at least 48 hours were included. Exclusion criteria were current treatment with other b-lactam agents, pregnancy, cystic fibrosis or chronic kidney disease, and an initial creatinine clearance (CrCl) < 30 ml/min. To account for the effect of VAN on AKI, patients were stratified by VAN exposure.
The primary outcome was incidence of AKI as defined by the Risk Injury Failure Loss and End-stage (RIFLE) criteria, an established method of identifying AKI. 9 Creatinine clearance was used as a marker for glomerular filtration rate (GFR) and was estimated by use of the adjusted Cockcroft-Gault equation. 10 Exposure to other nephrotoxic agents was defined as receipt of at least one dose within the 24 hours before treatment initiation through treatment discontinuation. Nephrotoxic agents included in this analysis were aminoglycosides, amphotericin B, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, intravenous radiocontrast dye, loop diuretics, nonsteroidal anti inflammatory drugs, calcineurin inhibitors, VAN, and vasopressors. Hypotension was defined as a composite of mean arterial pressure < 65 mm Hg, systolic blood pressure < 90 mm Hg, or vasopressor exposure during treatment. The Charlson Comorbidity Index (CCI) was used to approximate underlying severity of chronic illness. VAN , history of diabetes, heart failure, or hypertension. These variables were selected based on unadjusted associations with AKI in bivariate analysis and were equally weighted in the final propensity score model. Variables were analyzed in bivariate logistic regression with AKI as the response variable. All variables that were significant in simple regressions were included in the initial multivariate logistic regression of AKI. Variables were removed from the multivariate model in a stepwise fashion to minimize the Akaike Information Criterion to maximize model fit for the final multivariate model. Goodness-of-fit was tested with use of the Hosmer-Lemeshow test and the area under the receiver operator characteristic curve (ROC) or c-statistic. All tests were two-tailed, with an a of .05 considered significant. All data analyses were performed by using R v3.1.3 (R Foundation for Statistical Computing, Vienna, Austria) and RStudio v0.98 (RStudio, Inc., Boston, MA).
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Results
After matching, 2448 patients were analyzed for the primary outcome, with 1836 patients receiving PTZ and 612 receiving SAM. Baseline covariates were evenly distributed between groups (Table 1) , with the exceptions of CCI (5 [interquartile range (IQR) 2-9] vs 4 [IQR [1] [2] [3] [4] [5] [6] [7] [8] [9] in the SAM and PTZ groups, respectively; p=0.002) and intravenous (IV) radiocontrast dye exposure (3.3% vs 5.8% in SAM and PTZ groups, respectively; p=0.02). Overall, AKI incidence was similar between the SAM (9.2%) and PTZ groups (11.4%, p=0.15). However, PTZ was associated with higher rates of GFR reductions compared with SAM (> 50%: 1.5% vs 1.1%, p=0.02; and > 75%: 1.3% vs 0.2%, p=0.0001) ( Table 2) .
Vancomycin exposure was significantly associated with AKI independent of treatment group on bivariate logistic regression (odds ratio [OR] 1.07; 95% confidence interval [CI] 1.04-1.1) ( Table 3 ). The incidence of AKI was lowest in the SAM monotherapy group (8.9%) and highest in the PTZ plus vancomycin group (18.1%). The rates of AKI for PTZ monotherapy (9.5%) and SAM plus VAN (10.2%) were somewhat higher than for SAM monotherapy. After multivariate regression (Table 4) , there were no difference in the odds of AKI between SAM and PTZ (adjusted OR [aOR] 0.87, 95% CI 0.59-1.25); however, the addition of VAN to PTZ significantly increased the odds of AKI compared with PTZ monotherapy (aOR 1.77, 95% CI 1.26-2.46). The addition of VAN to SAM therapy did not increase the odds of AKI (aOR 1.01, 95% CI 0.48-1.97).
Additional factors that independently predicted AKI were duration of b-lactam therapy, history of heart failure, loop diuretic exposure, and calcineurin inhibitor exposure (Table 4) . There was no evidence of overfitting in the model with a Hosmer-Lemeshow p value of 0.37, and the model had an area under the ROC of 0.71. Data are n (%) unless specified otherwise. ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; IQR = interquartile range; NSAID = nonsteroidal anti inflammatory drug; PTZ = piperacillin-tazobactam; SAM = ampicillin-sulbactam; SD = standard deviation. 
Discussion
In this large retrospective cohort study, the incidence of AKI between two common b-lactam/ b-lactamase inhibitor combinations was similar after controlling for confounding factors associated with AKI. To our knowledge, this is the first study to examine this relationship.
The literature in this area describes a high variability in the rates of AKI associated with PTZ, mainly as combination therapy with VAN. One group reported the rate of PTZ monotherapy-associated AKI to be 15.4%, which was not significantly different from the combination therapy arm (18.8%). 8 AKI rates when PTZ is combined with VAN range from 9.5% to 34.8%. [1] [2] [3] [4] [5] [6] [7] [8] Few studies have compared AKI incidence among different treatment regimens, but the most common comparator is cefepime. Researchers found PTZ combined with VAN had significantly higher rates of AKI compared with the combination of cefepime and VAN (34.8% vs 12.5%). 4 In a study of patients with diabetic osteomyelitis, PTZ-VAN was associated with a non-statistically significant higher rate of AKI (29.3%) compared with cefepime-VAN (13.3%). 6 In addition, in critically ill patients, no difference in AKI incidence was noted between PTZ or cefepime when combined with VAN. 5 These studies used varying definitions of AKI and examined relatively small sample sizes. In addition, although cefepime and PTZ are commonly interchanged clinically, PTZ is distinct because of the addition of a b-lactamase inhibitor to the b-lactam. The unadjusted AKI rate in our study for patients in the PTZ arm was 22.2%; however, following matching the AKI rate was only 11.4% in the PTZ group (p=0.15). After stratification by VAN use, PTZ-VAN had higher rates of AKI compared with PTZ alone (18.1% vs 9.5%; aOR 1.77; 95% CI 1.26-2.46), which is consistent with prior literature.
Ampicillin-sulbactam is another b-lactam/blactamase inhibitor combination used intravenously for the treatment of a variety of infections. Nephrotoxicity data for SAM are limited; however, one small study of high-dose SAM for multidrug-resistant Acinetobacter baumanii pneumonia found AKI rates of approximately 15.3%. 15 Another study, examining SAM use in multidrug-resistant A. baumanii infections, found AKI renal failure occurred in 26% of patients. 16 These findings are limited by sample size and selection of critically ill patients, who have higher rates of nephrotoxicity. In contrast, we found that AKI occurred in 9.2% of patients receiving SAM. Distinct data for patients receiving SAM in combination with VAN are not readily available from earlier SAM studies. When stratified by VAN exposure, we found a numerical, but statistically insignificant, increase in AKI (10.2% SAM-VAN vs 8.9% SAM alone; aOR 1.01, 95% CI 0.48-1.97).
Despite the marked interest in the increase in nephrotoxicity noted with combination PTZ and VAN therapy, there have been no hypothesized pathophysiological mechanisms for this finding. We considered the addition of tazobactam to piperacillin as a possible contributing factor to the increase in AKI due to the administration of two b-lactam-like agents. This is specifically important when comparing PTZ-VAN with other b-lactam combinations that contain only a single b-lactam agent, such as cefepime or meropenem. Nephrotoxicity data for b-lactamase inhibitors administered alone are lacking. Ampicillinsulbactam is the only b-lactam/b-lactamase inhibitor agent commonly used as an alternative to PTZ at our institution. Our findings demonstrate that rates of AKI are similar among b-lactam/ b-lactamase inhibitor combinations at our institution and that the combination of VAN and PTZ is a major factor in AKI.
This study is not without limitations. While we used a robust analysis via matching patients on several possible confounders, there is still the possibility of unmeasured confounders in our sample. However, we did control for many nephrotoxic exposures, such as hypotension and other nephrotoxic drug administration, which should explain the majority of confounding in this study. In addition, we attempted to control for the temporal relation of nephrotoxic exposure to the treatment window of the study agents. For other nephrotoxic agents, doseresponse relationships were not assessed and all exposures were defined as receipt of at least one dose within 24 hours prior to initiation of study agents. This may overestimate the impact of those exposures on AKI, which in turn would bias our results toward the null hypothesis. Between-group differences in chronic illness, as assessed by the CCI, could bias results suggesting that SAM is more nephrotoxic than PTZ. However, our results show the opposite. Critical illness is not well captured by the CCI, and there is a chance that there was a higher proportion of critically ill patients in the PTZ arm. To counter this, we matched on presence of hypotension during the treatment period and baseline severity of illness. Finally, it is unclear if the nephrotoxic potentials of the b-lactam agents are similar. Due to the timeframe of this study, no patients received piperacillin monotherapy, which precludes any inference regarding the additional nephrotoxic potential of tazobactam. Further prospective studies of combination antimicrobial chemotherapy are warranted, as are animal and human studies of the mechanism for increased nephrotoxicity.
Conclusion
The rates of AKI for PTZ and SAM were similar in our large matched cohort study. In addition, concomitant vancomycin exposure was associated with significant increases in AKI incidence. The magnitude of increase was significantly different for PTZ compared with SAM.
